^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VLS-1488

    i
    Other names: VLS-1488
    Associations

    News

    Trials
    Company:
    Volastra Therap
    Drug class:
    KIF18A inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    KIF18A inhibition and its rising role in cancer therapy trials: from bench to bedside. (PubMed, Expert Opin Investig Drugs)
    We summarize the development of small-molecule inhibitors, from early compounds like BTB-1 to second-generation agents including Sovilnesib and VLS-1488, the latter currently in Phase I/II trials...New entrants like ATX-295 and GH2616 further expand the landscape...As clinical trials progress, optimizing patient stratification and exploring synergistic combinations will be crucial. Broadening the range of druggable sites on KIF18A, especially beyond the motor domain, could mitigate resistance and help expand therapeutic potential.
    Journal
    |
    KIF18A (Kinesin Family Member 18A)
    |
    VLS-1488 • sovilnesib (AMG 650)
    7ms
    A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=200, Recruiting, Volastra Therapeutics, Inc. | N=120 --> 200
    Enrollment change
    |
    VLS-1488
    7ms
    A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Volastra Therapeutics, Inc. | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    VLS-1488
    over2years
    A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Volastra Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    VLS-1488
    almost3years
    A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer (clinicaltrials.gov)
    P1/2, N=120, Not yet recruiting, Volastra Therapeutics, Inc.
    New P1/2 trial • Metastases
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    VLS-1488